Edesa Biotech, Inc. (EDSA), a clinical-stage biopharmaceutical company, on Tuesday reported positive results from a Phase 3 study evaluating paridiprubart, its drug candidate for the treatment of Acute Respiratory Distress Syndrome (ARDS).
The company said paridiprubart met the primary endpoint in the most conservative intention-to-treat (ITT) population, showing a statistically significant and clinically meaningful reduction in 28-day mortality.
Patients treated with paridiprubart plus standard of care (SOC) had a lower risk of death (39%), compared with 52% for those receiving placebo — an absolute improvement in survival of 13% and a 25% relative reduction in the risk of death versus placebo. Paridiprubart is also being evaluated in the U.S. government's Just Breathe study, which is investigating three novel, threat-agnostic therapeutics in hospitalized adult patients with ARDS.
For comments and feedback contact: editorial@rttnews.com
Economic News
What parts of the world are seeing the best (and worst) economic performances lately? Click here to check out our Econ Scorecard and find out! See up-to-the-moment rankings for the best and worst performers in GDP, unemployment rate, inflation and much more.
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.